Kanghong Pharmaceutical announced that the company's product, rifixime eye drops, were included in the “National Catalogue of Drugs for Basic Medical Insurance, Maternity Insurance and Work Injury Insurance”. The drug is classified as Class B and other ophthalmic drugs. The medical insurance payment standard is 4.90 yuan/branch, and the agreement is valid from January 1, 2027 to December 31, 2028. This product is suitable for treating the signs and symptoms of dry eye. The company is the first holder in China to complete its clinical research and be approved for marketing. This inclusion in medical insurance is expected to enhance the company's market competitiveness in the field of ophthalmology, have a positive effect on sales growth and long-term development, and the impact on current results cannot be accurately estimated.

Zhitongcaijing · 1d ago
Kanghong Pharmaceutical announced that the company's product, rifixime eye drops, were included in the “National Catalogue of Drugs for Basic Medical Insurance, Maternity Insurance and Work Injury Insurance”. The drug is classified as Class B and other ophthalmic drugs. The medical insurance payment standard is 4.90 yuan/branch, and the agreement is valid from January 1, 2027 to December 31, 2028. This product is suitable for treating the signs and symptoms of dry eye. The company is the first holder in China to complete its clinical research and be approved for marketing. This inclusion in medical insurance is expected to enhance the company's market competitiveness in the field of ophthalmology, have a positive effect on sales growth and long-term development, and the impact on current results cannot be accurately estimated.